An annotated corpus from biomedical articles to construct a drug-food interaction database

2022 ◽  
pp. 103985
Author(s):  
Siun Kim ◽  
Yoona Choi ◽  
Jung-Hyun Won ◽  
Jung Mi Oh ◽  
Howard Lee
2019 ◽  
Author(s):  
Rohit Ashok Khot ◽  
Florian Mueller
Keyword(s):  

2021 ◽  
Vol 1 (4) ◽  
Author(s):  
Coline Berthollier ◽  
Sylvain D. Vallet ◽  
Madeline Deniaud ◽  
Olivier Clerc ◽  
Sylvie Ricard‐Blum

2014 ◽  
Vol 38 (4) ◽  
pp. 485-495 ◽  
Author(s):  
Ashleigh Haynes ◽  
Eva Kemps ◽  
Robyn Moffitt ◽  
Philip Mohr

interactions ◽  
2020 ◽  
Vol 27 (5) ◽  
pp. 34-39
Author(s):  
Markéta Dolejšová ◽  
Hilary Davis ◽  
Ferran Altarriba Bertran ◽  
Danielle Wilde
Keyword(s):  

2014 ◽  
Vol 10 (10) ◽  
pp. 2713-2723 ◽  
Author(s):  
M. Burnette ◽  
T. Brito-Robinson ◽  
J. Li ◽  
J. Zartman

We describe a novel approach to screen for growth promoting compounds and score putative targets using a drug–protein interaction database.


1992 ◽  
Vol 32 (1) ◽  
pp. 32-36 ◽  
Author(s):  
Sou-yie Chu ◽  
Y. Park ◽  
Charles Locke ◽  
David S. Wilson ◽  
J. C. Cavanaugh

This chapter describes how OncoRx-MI, a pharmaco-informatics platform for detecting chemotherapy interactions, was designed through a pharmaco-cybernetics approach targeting the 5 activities of the digital health innovation process. This is the first database of its kind that is able to provide interaction information for anticancer drugs and chemotherapy regimen cocktails. In order to identify the gap and determine the usefulness of this database in clinical oncology practice, the quality of online anticancer drug interactions was assessed, and the perceptions of oncology practitioners were sought. The results showed that the accuracy of drug interaction content and the clinical usefulness of the database was highly regarded by these practitioners. In addition, evidence of its relevance and credibility was demonstrated through user feedback on the database.


Author(s):  
Hilde Tobi ◽  
Paul B. van den Berg ◽  
Lolkje T.W. de Jong-van den Berg
Keyword(s):  

2010 ◽  
Vol 3 ◽  
pp. HSI.S3679 ◽  
Author(s):  
◽  
Kevin Yi-Lwern Yap ◽  
Alexandre Chan ◽  
Keung Chui Wai

Cancer patients undergoing chemotherapy are particularly susceptible to drug-drug interactions (DDIs). Practitioners should keep themselves updated with the most current DDI information, particularly involving new anticancer drugs (ACDs). Databases can be useful to obtain up-to-date DDI information in a timely and efficient manner. Our objective was to investigate the DDI information sources of pharmacy practitioners in Asia and their views on the usefulness of an oncology-specific database for ACD interactions. A qualitative, cross-sectional survey was done to collect information on the respondents' practice characteristics, sources of DDI information and parameters useful in an ACD interaction database. Response rate was 49%. Electronic databases (70%), drug interaction textbooks (69%) and drug compendia (64%) were most commonly used. Majority (93%) indicated that a database catering towards ACD interactions was useful. Essential parameters that should be included in the database were the mechanism and severity of the detected interaction, and the presence of a management plan (98% each). This study has improved our understanding on the usefulness of various DDI information sources for ACD interactions among pharmacy practitioners in Asia. An oncology-specific DDI database targeting ACD interactions is definitely attractive for clinical practice.


Sign in / Sign up

Export Citation Format

Share Document